Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1991 1
1992 1
1994 1
1996 1
1997 2
1999 2
2000 1
2003 1
2006 1
2007 1
2008 1
2009 2
2010 1
2011 1
2015 1
2016 1
2017 1
2019 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
V-region-related and -unrelated immunosuppression accompanying infections.
Arala-Chaves M, Lima MR, Coutinho A, Pena-Rossi C, Minoprio P. Arala-Chaves M, et al. Among authors: pena rossi c. Mem Inst Oswaldo Cruz. 1992;87 Suppl 5:35-41. doi: 10.1590/s0074-02761992000900005. Mem Inst Oswaldo Cruz. 1992. PMID: 1342715 Free article. Review.
Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects.
Gillon JY, Dennison J, van den Berg F, Delhomme S, Dequatre Cheeseman K, Peña Rossi C, Strub Wourgaft N, Specht S, Pedrique B, Monnot F, Skrabs S, Rodriguez ML, Stass H. Gillon JY, et al. Among authors: pena rossi c. Br J Clin Pharmacol. 2021 Oct;87(10):3949-3960. doi: 10.1111/bcp.14816. Epub 2021 Mar 31. Br J Clin Pharmacol. 2021. PMID: 33759250 Free PMC article. Clinical Trial.
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese MC. Burmester GR, et al. Among authors: pena rossi c. RMD Open. 2019 Oct 18;5(2):e001017. doi: 10.1136/rmdopen-2019-001017. eCollection 2019. RMD Open. 2019. PMID: 31673415 Free PMC article. Clinical Trial.
B cell activities in normal unmanipulated mice.
Freitas A, Pereira P, Huetz F, Thomas-Vaslin V, Pena-Rossi C, Andrade L, Sundblad A, Forni L, Coutinho A. Freitas A, et al. Among authors: pena rossi c. Contrib Microbiol Immunol. 1989;11:1-26. Contrib Microbiol Immunol. 1989. PMID: 2684508 Review. No abstract available.
Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M; Onercept Study Group. Rutgeerts P, et al. Among authors: pena rossi c. Clin Gastroenterol Hepatol. 2006 Jul;4(7):888-93. doi: 10.1016/j.cgh.2006.04.022. Epub 2006 Jun 22. Clin Gastroenterol Hepatol. 2006. PMID: 16797249 Clinical Trial.
24 results